India EV Share Hits 8% as Tata, Mahindra Take 63% of BEV Sales

Image
India EV Share Hits 8% as Tata, Mahindra Take 63% of BEV Sales

Frankfurt – November 03, 2026 -- Battery-electric vehicles took more than 8% of Indian passenger car registrations in September 2026, and BEV registrations nearly doubled from a year earlier, according to FADA data cited by consultancy BearingPoint. Tata Motors and Mahindra & Mahindra together captured about 63% of those BEV registrations, narrowing the window for European carmakers to build a position.

The share of electric vehicles in Indian new-car registrations stood at just 4% at the end of 2025, per FADA. It has climbed steadily through 2026 and is approaching the 10% mark.

Urban buyers favor BEVs 39% to 17% over combustion cars

BearingPoint's international e-mobility study shows a gap between purchase intent and market reality. Among urban respondents likely to buy a vehicle within three years, 39% prefer a new BEV and 25% a hybrid or plug-in hybrid. Only 17% want a new petrol or diesel car.

Multiconsult Q3 EBITA plunges to NOK 6.3m on merger costs

OSLO – – November 03, 2026 -- Multiconsult's third-quarter EBITA fell to NOK 6.3 million from NOK 62.1 million a year earlier, cutting the margin to 0.5 per cent from 5.2 per cent as weak summer activity and merger-related costs weighed on earnings.

Net operating revenues rose 2.0 per cent to NOK 1,219.7 million (NOK 1,196.4 million). Organic growth, adjusted for calendar effects and acquisitions, was 0.1 per cent. The net loss was NOK 20.9 million against a profit of NOK 38.9 million, and earnings per share were NOK -0.74 (NOK 1.41).

Wincomm and Portwell Pool Medical AI Computing at MEDICA 2026

Image
Wincomm and Portwell Pool Medical AI Computing at MEDICA 2026

HSINCHU – November 03, 2026 -- Wincomm, a Portwell company, will exhibit alongside Portwell Taiwan and Portwell Europe at MEDICA 2026 (November 16-19, Düsseldorf, Germany), with a joint stand at Hall 12, Stand C76 covering embedded computing, medical All-in-One (AIO) PCs and portable devices.

Joint stand targets medical equipment makers and system integrators

The three entities will combine product engineering expertise with regional support. Their stated aim is to help medical equipment manufacturers and system integrators identify suitable computing architectures for their applications.

The companies cite growing demand for more diverse computing platforms tailored to different workloads, power requirements, installation constraints and system integration needs. By showing their complementary portfolios together, they aim to give visitors a broader view of platforms for connected medical equipment and AI deployment at the clinical edge.

Elron Ventures Reshapes Board as It Targets $300M Defense M&A Push

Image
Elron Ventures Reshapes Board as It Targets $300M Defense M&A Push

TEL AVIV – November 03, 2026 -- Elron Ventures Ltd. (TASE: ELRN) has appointed three new directors and an interim chairman, and is searching for a new CFO, as it prepares to deploy up to $300 million in a defense and dual-use acquisition program with Rafael Advanced Defense Systems.

Dan Hoz returns as interim chairman after prior stint at the helm

Board member Dan Hoz becomes Interim Chairman. He previously chaired Elron and is familiar with its portfolio companies and strategy. Hoz was Managing Director of Siemens EDA in Israel, Vice President at Siemens Digital Industries Software, and earlier CEO of Valor.

Former Cellebrite CFO Dana Gerner joins as external director

Dana Gerner, previously Chief Financial Officer of Cellebrite, takes an External Director seat. Elron cites her record in growth strategy, capital markets activity and investor relations at global, publicly traded technology companies.

Nordic Launches nRF71 Chip With Wi-Fi, Thread, BLE and Edge AI

Image
Nordic Launches nRF71 Chip With Wi-Fi, Thread, BLE and Edge AI

Oslo – November 03, 2026 -- Nordic Semiconductor has introduced the nRF71 Series of ultra-low-power systems-on-chip, which cuts standby power by up to 20 times compared with the current nRF70 Series Wi-Fi products. The chips combine Wi-Fi, Bluetooth Low Energy (LE), Thread and edge AI on a single device and are now sampling with selected customers.

Axon NPU runs machine learning models 10x to 17x faster than the Cortex-M33 alone

The integrated Axon Neural Processing Unit runs inference 10x to 17x faster than the 256 MHz Arm Cortex-M33 processor alone. Nordic says keyword spotting, anomaly detection and image classification become practical on battery-powered devices, with no external AI processor required. Developers can also run ultra-small models built from their own data with Nordic's Neuton software on the processor alone. Over-the-air model updates run through nRF Cloud.

Hays Index: German Skilled-Worker Demand Rises to 39% in Q3

Image
Hays Index: German Skilled-Worker Demand Rises to 39% in Q3

Mannheim – November 03, 2026 -- German demand for skilled professionals rose three percentage points in the third quarter, lifting the Hays Skilled-Worker Index from 36 to 39 percent after a sharp drop in spring. Hiring remains selective: companies continue to cut jobs and postpone replacements while recruiting for roles of strategic, regulatory or operational importance.

Construction index reaches 212 percent, up from 136 percent a year earlier

Construction posted the highest demand of all sectors surveyed. Engineer demand rose four percentage points quarter on quarter, led by civil, electrical and project engineers. Automation engineers gained 28 percentage points, design engineers 19 and process engineers 12.

German Builders Warn Visa Cut Would Cost 9,000 Workers

Berlin – November 03, 2026 -- Germany's construction industry says a planned halving of the Western Balkans visa scheme would leave the sector almost 9,000 workers short, according to calculations by the Central Association of the German Construction Industry (ZDB). The federal cabinet is due to discuss the cut on Wednesday.

Labor ministry draft would cap first-time approvals at 25,000 from 2027

Under a draft from the Federal Ministry of Labour, the Federal Employment Agency would grant only 25,000 initial approvals per year from January 1, 2027, down from 50,000. The scheme links legal labor migration to a concrete job offer. The ZDB is urging the government not to wave the reduction through.

PwC: Asset Manager Profit per AuM Down 19% as Tech Costs Climb

Image
PwC: Asset Manager Profit per AuM Down 19% as Tech Costs Climb

LUXEMBOURG – November 03, 2026 -- Asset managers' profit per unit of assets under management has fallen 19% since 2018 and is projected to drop another 9.1% by 2030, according to PwC's Global Asset Management Infrastructure report. Decisions on what to build, buy or access through partners now shape how firms compete.

Fee compression limits the ability to invest for 67% of respondents. Only 23% direct most of their technology budget to new capabilities, while 29% spend more than 70% of it maintaining legacy systems. The survey covered 150 asset managers and 50 infrastructure providers.

Sobi to present six gout abstracts at ACR Convergence 2026

Stockholm – November 03, 2026 -- Sobi (STO: SOBI) will present six abstracts on two late-stage gout assets, pozdeutinurad (AR882) and nanoencapsulated sirolimus plus pegadricase (NASP), at ACR Convergence 2026, the American College of Rheumatology annual meeting, in Orlando, Florida, on 6–11 November 2026.

Phase 3 REDUCE-2 results for pozdeutinurad headline the program

The presentations include results from the Phase 3 REDUCE-2 study of pozdeutinurad, an investigational once-daily oral, highly selective URAT1 inhibitor for uncontrolled gout. REDUCE-2 is one of two 12-month, randomised, double-blind, placebo-controlled Phase 3 studies, alongside REDUCE-1, that are evaluating the drug in more than 800 patients. Both trials assess its ability to lower serum urate (SU) in patients with uncontrolled gout.

Earlier Phase 2 studies showed a sustained SU reduction, dissolution of tophi and a generally well-tolerated safety profile, according to Sobi.

Moberg Pharma Wins U.S. Patent on MOB-015 Dosing, Expiry 2041

STOCKHOLM – November 03, 2026 -- The U.S. Patent and Trademark Office has granted Moberg Pharma a patent on an improved dosing regimen for MOB-015, its topical onychomycosis drug, with a projected expiry in December 2041. The U.S. is the first market to grant a patent on the new dosing.

Patent draws on European approval studies and North American Phase 3 data

The patent covers new dosing approaches for MOB-015. It rests on clinical results from the studies behind the European approval and from the company's most recently completed Phase 3 study in North America. Dosing patent applications in other markets remain under examination.